Skip to main content

What the FDA labels say about taking them together

Cisplatin and paclitaxel

Paclitaxel's FDA label of January 21, 2026 names cisplatin in its drug interactions section; the cisplatin label PlainMeds reads does not name paclitaxel. The paclitaxel label: “Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when paclitaxel was administered following cisplatin.”

Check it at the source: the cisplatin FDA label on DailyMed (effective September 16, 2021, WG Critical Care, LLC); the paclitaxel FDA label on DailyMed (effective January 21, 2026, Natco Pharma USA LLC).

What does the cisplatin label say about paclitaxel?

Cisplatin's label (effective September 16, 2021) does not name paclitaxel in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (CISplatin), NDA018057 (Hq Spclt Pharma), as published by WG Critical Care, LLC, effective September 16, 2021 (SPL set 2bf8d2fb-80c8-401d-8e9b-d58463f5e954), via openFDA; the full label on DailyMed

What does the paclitaxel label say about cisplatin?

Paclitaxel label, drug interactions

Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when paclitaxel was administered following cisplatin.

Source: FDA drug label (Paclitaxel), Natco Pharma USA LLC, effective January 21, 2026 (SPL set a1eb16b4-285b-4e81-9c4e-1244d4a52af8), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

9Cisplatin generic labelers
19Paclitaxel generic labelers
CisplatinPaclitaxel
Labeled forn/aBreast cancer, Lung cancer
Boxed warningYesYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?